Bronnen:
Onda T, Satoh T, Toshiaki Saito, et al. Comparison of survival between upfront primary debulking surgery versus neoadjuvant chemotherapy for stage III/IV ovarian, tubal and peritoneal cancers in phase III randomized trial: JCOG0602. ASCO 2018. J Clin Oncol 36, 2018 (suppl; abstr 5500).,Onda T, Satoh T, Saito T, et al.; Japan Clinical Oncology Group. Comparison of treatment invasiveness between upfront debulking surgery versus interval debulking surgery following neoadjuvant chemotherapy for stage III/IV ovarian, tubal, and peritoneal cancers in a phase III randomised trial: Japan Clinical Oncology Group Study JCOG0602. Eur J Cancer 2016;64:22-31.
Onda T, Satoh T, Toshiaki Saito, et al. Comparison of survival between upfront primary debulking surgery versus neoadjuvant chemotherapy for stage III/IV ovarian, tubal and peritoneal cancers in phase III randomized trial: JCOG0602. ASCO 2018. J Clin Oncol 36, 2018 (suppl; abstr 5500).,Onda T, Satoh T, Saito T, et al.; Japan Clinical Oncology Group. Comparison of treatment invasiveness between upfront debulking surgery versus interval debulking surgery following neoadjuvant chemotherapy for stage III/IV ovarian, tubal, and peritoneal cancers in a phase III randomised trial: Japan Clinical Oncology Group Study JCOG0602. Eur J Cancer 2016;64:22-31.